Verition Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Verition Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,409	Closed	-$623K	–	2338
2025 Q4	$623K	Buy	3,409 +1,420	+71%	+$198K	﹤0.01%	2494
2025 Q3	$242K	Buy	+1,989	New	+$224K	﹤0.01%	3398
2025 Q2	–	Sell	-28,998	Closed	-$3.38M	–	3632
2025 Q1	$3.38M	Buy	28,998 +23,650	+442%	+$2.69M	0.02%	1175
2024 Q4	$452K	Buy	+5,348	New	+$492K	﹤0.01%	2543
2023 Q2	–	Sell	-9,316	Closed	-$575K	–	2206
2023 Q1	$575K	Buy	+9,316	New	+$612K	0.01%	1162
2022 Q4	–	Sell	-10,943	Closed	-$488K	–	2145
2022 Q3	$488K	Buy	+10,943	New	+$547K	0.01%	1904
2020 Q2	–	Sell	-33,200	Closed	-$1.95M	–	1052
2020 Q1	$1.95M	Buy	+33,200	New	+$2.71M	0.08%	172

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's AXSM Position: Q1 2026 in Review

Verition Fund Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 3,409 shares — an estimated $623K sold.

Verition Fund Management first reported a position in AXSM in Q1 2020 and held it in 7 quarters. The position peaked at $3.38M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Verition Fund Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 3,409 Axsome Therapeutics shares in Q1 2026, an estimated $623K.
Verition Fund Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 7 quarters.
Verition Fund Management's Axsome Therapeutics position peaked at $3.38M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.